




FIG. 1A







FIG. 1B

FIG. 1










FIG. 3B


FIG. 3

FIG. 3A



RM-006 10 mg/kg ip
AMG 510 100 mg/kg po
Combination
Unbound plasma [RM-006 10 mg/kg ip]
Unbound plasma [AMG 510 100 mg/kg po]
(N=3/group for PKPD, except N=2 for combination 24hr PD)


FIG. 4



IHC: pS6RP (S235) staining

FIG. 4E


FIG. 4 (Cont. 1)



IHC: p4EBP1 staining

FIG. 4F

FIG. 4 (Cont. 2)



NCI-H2030 KRAS^{G12C}; STK11^{E317*} NSCLC CDX





FIG. 6B

FIG. 6

FIG. 6A







FIG. 8



All doses tolerated as assessed by body weights

Compound A is an advanced KRAS^{G12C}(ON) tool compound

FIG. 9





FIG. 10



All doses tolerated as assessed by body weights

Compound B is a KRASG12C(ON) inhibitor

FIG. 11